BRÈVE

sur IAVI

Ebola Sudan Vaccine Candidate Deployed Amid Uganda Outbreak

The nonprofit research organization IAVI has begun vaccinating participants in Uganda with its investigational Ebola Sudan vaccine. This initiative is part of a ring vaccination trial led by the World Health Organization (WHO) at Makerere University Lung Institute in Kampala. The vaccine trial is central to a global collaboration aimed at addressing Uganda's sixth Ebola Sudan outbreak, marked by a high fatality rate of up to 50%.

The outbreak, which began on January 30 with a fatal case, has identified 45 close contacts prioritized for vaccination. The ring vaccination approach, previously effective in the Democratic Republic of the Congo, employs the same viral vector platform as IAVI’s vaccine. This method promises rapid mobilization and potential effectiveness despite no current licensed vaccines for Ebola Sudan.

Initial studies in the U.S. showed promising tolerance and immune responses from the vaccine candidate, laying the groundwork for future trials in Africa. This effort reflects a significant step in developing a viable Ebola Sudan vaccine as part of broader epidemic preparedness.

R. H.

Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de IAVI